Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 88
- Registration Number
- NCT00453635
- Locations
- 🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷Air Forces Military Hospital of Athens, Athens, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 419
- Registration Number
- NCT00441740
- Locations
- 🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷"Metaxa's" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Athens, Greece
🇬🇷" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens, Greece
Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 166
- Registration Number
- NCT00441922
- Locations
- 🇬🇷
Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki, Greece
🇬🇷University General Hospital of Alexandroupolis, Department of Medical Oncology, Alexandroupolis, Greece
🇬🇷401 Military Hospital of Athens, Athens, Greece
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
- Conditions
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2011-03-14
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Registration Number
- NCT00433095
- Locations
- 🇩🇪
University of Munich - Klinikum Grosshdern, Munich, Germany
VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 39
- Registration Number
- NCT00431704
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy
Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 144
- Registration Number
- NCT00431106
- Locations
- 🇬🇷
401 Military Hospital of Athens, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dept. of Medical Oncology, Alexandroupolis, Greece
🇬🇷"IASO" General Hospital of Athens, 1st Dept. of Medical Oncology, Athens, Greece
Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2008-05-09
- Lead Sponsor
- Danish Breast Cancer Cooperative Group
- Target Recruit Count
- 300
- Registration Number
- NCT00430001
- Locations
- 🇩🇰
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma
- Conditions
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2008-11-04
- Lead Sponsor
- American University of Beirut Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00403988
- Locations
- 🇱🇧
AmericanUBMC, Beirut, Lebanon
HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 50
- Registration Number
- NCT00401427
MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 159
- Registration Number
- NCT00401492
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.